Valuation: Rezolute, Inc.

Market Cap 489M 422M 396M 361M 678M 46.75B 688M 4.64B 1.82B 23.42B 1.84B 1.8B 77.9B P/E 2026 *
-6.69x
P/E 2027 * -7.2x
Enterprise Value 489M 422M 396M 361M 678M 46.75B 688M 4.64B 1.82B 23.42B 1.84B 1.8B 77.9B EV / Sales 2026 *
-
EV / Sales 2027 * 212x
Free-Float
89.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Rezolute, Inc.

1 day+1.74%
Current month-0.85%
1 month+1.52%
3 months+40.12%
6 months+28.93%
Current year+98.31%
1 week 4.44
Extreme 4.44
4.88
1 month 4.4
Extreme 4.395
5.4
Current year 1.87
Extreme 1.87
5.42
1 year 1.07
Extreme 1.07
11.46
3 years 0.72
Extreme 0.72
11.46
5 years 0.72
Extreme 0.72
11.46
10 years 0.72
Extreme 0.72
100
Manager TitleAgeSince
Chief Executive Officer 58 30/01/2013
Director of Finance/CFO 52 23/01/2024
Chief Operating Officer - -
Director TitleAgeSince
Chairman 58 04/05/2022
Director/Board Member 55 20/11/2019
Chairman 68 10/02/2019
Date Insider Type Main position Quantity % Market Cap.
7/2/26 A Tax

Chief Technology Officer

-3,062 0.0035%
7/2/26 A Tax

Chief Financial Officer

-3,062 0.0035%
7/2/26 A Tax

Chief Executive Officer

-8,004 0.0092%
Change 5-day change 1-year change 3-year change Capi.($)
+1.74%0.00%-28.00%+214.09% 489M
+4.80%+3.44%+70.64%+109.32% 73.25B
-0.35%+13.81%+48.66%+89.97% 61.95B
+3.70%-4.77%+0.41%+484.07% 28.02B
+5.24%+5.65%+56.71%+21.30% 24.15B
-1.60%-1.29%-19.31%-19.10% 23.01B
-6.00%+6.02%+244.39%+430.80% 18.35B
+0.55%+6.12%+40.30%-13.85% 19.46B
+3.83%+2.65%+21.42%+557.58% 15.92B
+2.11%-1.21%+36.57%+149.14% 12.96B
Average +1.01%+0.95%+47.18%+202.33% 27.76B
Weighted average by Cap. +1.46%+3.13%+54.75%+164.90%

Financials

2026 *2027 *
Net sales - 2.3M 1.99M 1.87M 1.7M 3.2M 220M 3.24M 21.88M 8.57M 110M 8.65M 8.46M 367M
Net income -72.7M -62.76M -58.88M -53.63M -101M -6.95B -102M -690M -270M -3.48B -273M -267M -11.58B -75.12M -64.85M -60.84M -55.41M -104M -7.18B -106M -713M -279M -3.6B -282M -276M -11.97B
Net Debt - -
Logo Rezolute, Inc.
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Employees
68
Date Price Change Volume
17/08/26 $4.680 +1.74% 535,242
14/08/26 $4.600 0.00% 657,137
13/08/26 $4.600 -2.13% 800,613
12/08/26 $4.700 +1.73% 2,391,287
11/08/26 $4.620 -1.28% 641,977
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.680USD
Average target price
7.667USD
Spread / Average Target
+63.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RZLT Stock